SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 24 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTERIM DATA FROM OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：5

作者：

Nash, P. ^{[1
]}

Coates, L. C. ^{[2
]}

Kivitz, A. J. ^{[3
]}

Mease, P. J. ^{[4
,5
]}

Gladman, D. D. ^{[6
]}

Covarrubias-Cobos, J. A. ^{[7
]}

Fleishaker, D. ^{[8
]}

Wang, C. ^{[8
]}

Kudlacz, E. ^{[8
]}

Menon, S. ^{[8
]}

Hendrikx, T. ^{[9
]}

Kanik, K. S. ^{[8
]}

机构：

[1] Univ Queensland, Dept Med, Brisbane, Qld, Australia

[2] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[3] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[4] Swedish Med Ctr, Seattle, WA USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Univ Toronto, Toronto Western Hosp, Dept Med, Toronto, ON, Canada

[7] Unidad Reumatol Las Amer SCP, Merida, Yucatan, Mexico

[8] Pfizer Inc, Groton, CT 06340 USA

[9] Pfizer Inc, Collegeville, PA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.1414

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0509

引用

页码：682 / 682

页数：1

共 50 条

[1] Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis: Interim data from OPAL Balance, an open label, long-term extension study
Nash, Peter
Coates, Laura C.
Kivitz, Alan J.
Mease, Philip J.
Gladman, Dafna D.
Covarrubias-Cobos, Jose A.
Kudlacz, Elizabeth
Menon, Sujatha
Kanik, Keith S.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB224 - AB224
[2] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Nash, Peter
Coates, Laura C.
Kivitz, Alan J.
Mease, Philip J.
Gladman, Dafna D.
Covarrubias-Cobos, Jose A.
Fleishaker, Dona
Wang, Cunshan
Kudlacz, Elizabeth
Menon, Sujatha
Fallon, Lara
Hendrikx, Thijs
Kanik, Keith S.
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[3] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE SECOND INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
Nash, P.
Coates, L. C.
Kivitz, A. J.
Mease, P. J.
Gladman, D. D.
Covarrubias-Cobos, J. A.
Fleishaker, D.
Wang, C.
Kudlacz, E.
Menon, S.
Hendrikx, T.
Kanik, K. S.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S109 - S109
[4] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Nash, Peter
Coates, Laura C.
Kivitz, Alan J.
Mease, Philip J.
Gladman, Dafna D.
Covarrubias-Cobos, Jose A.
Fleishaker, Dona
Wang, Cunshan
Kudlacz, Elizabeth
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith S.
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[5] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
Nash, P.
Coates, L. C.
Kivitz, A. J.
Mease, P. J.
Gladman, D. D.
Covarrubias-Cobos, A.
Fleishaker, D.
Wang, C.
Kudlacz, E.
Menon, S.
Fallon, L.
Hendrikx, T.
Kanik, K. S.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1010 - 1011
[6] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
Nash, P.
Coates, L. C.
Kivitz, A. J.
Mease, P. J.
Gladman, D. D.
Covarrubias-Cobos, J. A.
Fleishaker, D.
Wang, C.
Kudlacz, E.
Menon, S.
Fallon, L.
Hendrikx, T.
Kanik, K. S.
INTERNAL MEDICINE JOURNAL, 2018, 48 : 15 - 15
[7] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Nash, Peter
Coates, Laura C.
Kivitz, Alan
Mease, Philip J.
Gladman, Dafna D.
Covarrubias-Cobos, Jose A.
Fitzgerald, Oliver
Fleishaker, Dona
Wang, Cunshan
Wu, Joseph
Hsu, Ming-Ann
Menon, Sujatha
Fallon, Lara
Romero, Ana Belen
Kanik, Keith S.
RHEUMATOLOGY AND THERAPY, 2020, 7 (03) : 553 - 580
[8] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Peter Nash
Laura C. Coates
Alan J. Kivitz
Philip J. Mease
Dafna D. Gladman
José A. Covarrubias-Cobos
Oliver FitzGerald
Dona Fleishaker
Cunshan Wang
Joseph Wu
Ming-Ann Hsu
Sujatha Menon
Lara Fallon
Ana Belén Romero
Keith S. Kanik
Rheumatology and Therapy, 2020, 7 : 553 - 580
[9] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Wollenhaupt, Jurgen
Silverfield, Joel C.
Lee, Eun Bong
Wood, Susan P.
Soma, Koshika
Wang, Lisy
Nakamura, Hiroyuki
Komuro, Yoshihiro
Nduaka, Chudi I.
Gruben, David
Benda, Birgitta
Zwillich, Samuel H.
Riese, Richard
Bradley, John D.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S549
[10] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Wollenhaupt, Juergen
Silverfield, Joel
Lee, Eun Bong
Wood, Susan P.
Terry, Ketti K.
Nakamura, Hiroyuki
Ohno, Yukako
Gruben, David
Benda, Birgitta
Wang, Lisy
Riese, Richard
ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993

← 1 2 3 4 5 →